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Objectives: Third-generation cephalosporin-resistant Escherichia coli from community-25 
acquired urinary tract infections (UTI) are increasingly reported worldwide. We sought to 26 
determine and characterise the mechanisms of cefotaxime-resistance (CTX-R) employed by 27 
urinary E. coli obtained from primary care, over 12 months, in Bristol and surrounding counties 28 
in the South West of England.   29 
Methods: Cephalexin resistant (Ceph-R) E. coli isolates were identified from general practice 30 
(GP) referred urine samples using disc susceptibility testing. CTX-R was determined by 31 
subsequent plating onto MIC breakpoint plates. β-Lactamase genes were detected by PCR. 32 
WGS was performed on 225 isolates and analyses were performed using the Centre for 33 
Genomic Epidemiology platform. Patient information provided by the referring GPs was 34 
reviewed. 35 
Results: Ceph-R E. coli (n=900) were obtained from urines from 146 GPs. Seventy-percent 36 
(626/900) of isolates were CTX-R. WGS of 225 isolates identified that the most common CTX-37 
R mechanism was blaCTX-M carriage (185/225), followed by plasmid mediated AmpCs 38 
(pAmpCs) (17/225), ESBL blaSHV variants (6/225), AmpC-hyperproduction (13/225), or a 39 
combination of both blaCTX-M and pAmpC (4/225). Forty-four STs were identified with ST131 40 
representing 101/225 isolates, within which clade C2 was dominant (54/101). Ciprofloxacin-41 
resistance (CIP-R) was observed in 128/225 (56.9%) of sequenced isolates – predominantly 42 
associated with fluoroquinolone-resistant clones ST131 and ST1193. 43 
Conclusions: Most Ceph-R E. coli’s were CTX-R, predominantly caused by blaCTX-M carriage. 44 
The correlation between CTX-R and CIP-R was largely attributable to the high-risk pandemic 45 
clones, ST131 and ST1193. Localised epidemiological data provides greater resolution than 46 






Escherichia coli that are resistant to β-lactam antibiotics, particularly to cephalosporins, 51 
represent a major global public health concern. Third-generation cephalosporins (3GCs) are 52 
used across the world to treat infections caused by E. coli (e.g. urinary tract [UTIs], 53 
bloodstream [BSIs] and intra-abdominal infections) and subsequently the emergence of 54 
resistance is particularly worrying.1 Resistance to 3GCs in E. coli can be caused by multiple 55 
mechanisms including chromosomally encoded AmpC β-lactamase hyperproduction, and 56 
may involve increased efflux, and reduced outer membrane permeability, but is predominantly 57 
attributed to the spread of plasmid-mediated ESBLs, (e.g. blaCTX-M) and to a lesser extent, 58 
plasmid mediated AmpCs (pAmpC, e.g. blaCMY).2 E. coli which harbour ESBLs are often co-59 
resistant to multiple antibiotic classes and subsequently the treatment options for such 60 
infections may be limited.3  61 
UTIs are the most common bacterial infection type in both primary and hospital care settings 62 
in the developed world,4 and are associated with considerable morbidity.5 Previous studies of 63 
community-onset UTIs (CO-UTI) in several mainland European countries found that E. coli 64 
were the most commonly isolated uropathogen, accounting for over half of all isolates (53.3-65 
76.7%).6-8 The incidence of CO-UTI in the UK is difficult to determine since such infections are 66 
not reportable and most are diagnosed and treated in a primary care setting, with diagnosis 67 
often based solely upon patient symptoms rather than a positive urine culture. CO-UTI are 68 
most often treated empirically and subsequently local epidemiological data is useful for 69 
informing treatment choice. Treatment failure for CO-UTIs, particularly in immune-70 
compromised patients, increases the risk of the infection spreading to other sites including the 71 
bloodstream, with grave consequences.9, 10  72 
E. coli STs belonging to phylogroups B2 (STs 73, 95 and 131) and D (ST69) have been 73 
reported to be major causes of both UTIs and BSIs in the UK.11 Since its initial description in 74 
2008, numerous studies have shown that the multidrug-resistant pandemic clone, ST131, is a 75 
major cause of UTI globally.12-14 The ST131 clonal group can be broken down by population 76 
 
 
genetics into three clades based on their association with particular fimH types: A/fimH41, 77 
B/fimH22, and C/fimH30.15 Clade C can be further broken down into four subclades; C1 – not 78 
usually associated with ESBL carriage but typically fluoroquinolone resistant (FQ-R), C1-M27 79 
and C1-nM27 – both associated with blaCTX-M-27 carriage and FQ-R, and C2 (also known as 80 
H30Rx) – associated with blaCTX-M-15 carriage and FQ-R.15, 16 Studies have suggested that the 81 
global dominance of ESBL-positive ST131 is, in part, due to its increased virulence potential 82 
over its non-ST131 ESBL-positive counterparts.17, 18  83 
Although cephalosporin use for the treatment of UTIs is not typical in the UK, they may be 84 
used where resistance to first and second-line treatment exists. This may select cephalosporin 85 
resistant UTIs, and if an invasive infection occurs, empiric therapy with a 3GC is likely to fail. 86 
This study sought to use WGS to characterise the population structure and determine the 87 
mechanisms of resistance to the 3GC cefotaxime (CTX-R) employed by urinary E. coli isolates 88 
referred from general practices (GPs) in Bristol and surrounding counties in the South-West 89 
of England serving a population of approximately 1.2 million people. 90 
 91 
Materials and Methods   92 
Bacterial isolates, identification and susceptibility testing 93 
Cephalexin-resistant (Ceph-R) urinary E. coli isolates were obtained from routine urine 94 
microbiology at Severn Infection Partnership Southmead Hospital. Urine samples were 95 
submitted between Sept 2017 and Aug 2018, from 146 GPs located throughout Bristol and 96 
including coverage in Gloucestershire, Somerset and Wiltshire.  97 
Bacterial identification was carried out using BD CHROMagar Orientation Medium 98 
chromogenic agar (BD, GmbH, Heidelberg, Germany). 99 
Antibiotic susceptibilities were performed by disc testing or, in the case of colistin, by broth 100 
microdilution and interpreted according to EUCAST guidelines.19 A single colony from Ceph-101 
 
 
R isolates was subcultured onto TBX agar plates (Sigma-Aldrich, Dorset, UK) containing 2 102 
mg/L CTX and isolates that were positive for growth were deemed CTX-R, and taken forward 103 
for further molecular testing.  104 
Screening for β-lactamase genes 105 
Two multiplex PCRs were performed to screen for β-lactamase genes. The first to detect 106 
blaCTX-M groups as previously described,20 and the second to detect the following additional β-107 
lactamase genes; blaCMY-2 type, blaDHA, blaSHV, blaTEM, blaOXA-1, using the primers listed in Table 108 
S1. 109 
WGS and analyses 110 
WGS was performed by MicrobesNG (https://microbesng.uk/) on a HiSeq 2500 instrument 111 
(Illumina, San Diego, CA, USA) using 2x250 bp paired end reads. Reads were trimmed using 112 
Trimmomatic,21 assembled into contigs using SPAdes22 3.13.0 113 
(http://cab.spbu.ru/software/spades/) and contigs were annotated using Prokka.23 Resistance 114 
genes, plasmid replicon types, sequence types and fim types were assigned using the 115 
ResFinder,24 PlasmidFinder,25 MLST26 2.0 and FimTyper on the Center for Genomic 116 
Epidemiology (http://www.genomicepidemiology.org/) platform. 117 
ST131 clades were identified by resistance gene carriage and fimH type, and in the case of 118 
clade C1-M27, by the presence of the prophage region M27PP1 (CP006632)16 through 119 
sequence alignment using progressive Mauve alignment software.27 120 
MLST and resistance gene data were analysed to produce a minimum spanning tree using 121 
Bionumerics software v7.6 (Applied Maths, Sint-Martens-Latem, Belgium). 122 
Plasmid pUB_DHA-1 assembled onto a single contig. The overlap of contig ends was 123 
confirmed by PCR, and the plasmid sequence was submitted to GenBank with accession 124 




Plasmid Transformation 127 
Transformation of plasmid extractions from isolates encoding mcr-1 and blaOXA-244 were 128 
attempted by electroporation using E. coli DH5 alpha as a recipient. Transformants were 129 
selected, respectively, on LB agar containing 0.5 mg/L colistin, or containing 100 mg/L 130 
ampicillin with a 10 µg ertapenem disc being placed on the agar surface (Oxoid Ltd, 131 
Basingstoke, UK). Transformants were confirmed by PCR (Table S1). 132 
Analysis of patient demographic information 133 
Limited, non-identifiable patient information was obtained from the request forms sent with 134 
submissions from referring GPs.  135 
 136 
Results and Discussion 137 
Patient demographics and antimicrobial susceptibilities 138 
E. coli is cultured from approximately two-thirds of all bacterium-positive GP-submitted urine 139 
samples processed by the Southmead Hospital laboratory, totalling ~36,000 isolates per year 140 
. Trimethoprim and nitrofurantoin resistance is observed in ~35% and 2%, and Ceph-R in ~8% 141 
of these E. coli, respectively. If the E. coli is Ceph-R, trimethoprim and nitrofurantoin resistance 142 
rates increase to ~67% and ~7%, respectively. 3GC resistance is seen in ~72% of Ceph-R E. 143 
coli. 144 
Nine hundred Ceph-R urinary E. coli isolates were collected during the period of our study. 145 
Following deduplication by patient, isolates were obtained from 836 patients. Most isolates 146 
were obtained from female patients (669/836; 80.0%) and the mean patient age was 62.4 147 
years (median = 69 years). Almost sixty-nine percent (576/836) were CTX-R, which matches 148 
phenotypic laboratory data, confirming that this is a representative sample. Most CTX-R 149 
isolates were again from females (465/576; 80.7%) and the mean patient age was 62.5 years 150 




β-Lactamase genes of interest detected by PCR in CTX-R isolates 153 
Table 1 indicates the number of CTX-R isolates carrying each β-lactamase gene of interest 154 
(GOI): blaCTX-Ms, blaCMY, blaDHA or blaSHV. Of these, blaCTX-Ms were by far the most prevalent, 155 
found in 571/626 (91.2%) of isolates. Within these, blaCTX-M-G1 were most common (421/626) 156 
followed by blaCTX-M-G9 (149/626) and blaCTX-M-G8 (one isolate). A previous study performed 157 
across four primary care trusts in England in 2013-14 estimated the carriage of CTX-M-158 
producing Enterobacteriaceae in the faeces of healthy adults at 7.3% (range of 4.9-16.0%), 159 
over 95% of which were E. coli.28 Based on our data above, 5.3% of GP-submitted urinary E. 160 
coli were CTX-M positive.  161 
pAmpCs blaCMY and blaDHA were found in 13 (3 alongside blaCTX-M-G1) and 17 (4 alongside 162 
blaCTX-M-G1) isolates respectively. blaSHV was found in 11 (3 alongside blaCTX-M-G1) isolates and 163 
the remaining 24 isolates harboured none of the GOIs as detected by PCR. 164 
Whole Genome Sequencing (WGS) analyses 165 
GOI variants and STs 166 
Two-hundred and twenty-five isolates, chosen to be representative of resistance gene 167 
carriage (as previously determined by PCR) and patient demographics (age, sex) obtained 168 
throughout the entire study period, were selected for WGS. Within these, 44 sequence types 169 
(STs) were identified, with numbers of isolates ranging from 1 to 101 representatives. ST131 170 
was dominant (n=101), followed by STs 69 (n=15), 73 (n=15), 38 (n=13), 1193 (n=11), and 10 171 
(n=8). The remaining 38 STs had 1 to 4 representative isolates (Figure 1).  172 
CTX-R GOIs were identified in all but thirteen isolates (212/225; 94.2%). Eighty-four percent 173 
(189/225) of isolates harboured one of seven blaCTX-M gene variants (Table 2). Carriage of 174 
blaCTX-M-15 was the most common CTX-R mechanism identified (118/189) followed by blaCTX-M-175 
27 (44/189) and blaCTX-M-14 (10/189). Amongst the non-CTX-M GOIs, four blaCMY variants were 176 
 
 
identified; blaCMY-2 (n=7), blaCMY-4 (n=1), blaCMY-42 (n=2) and blaCMY-60 (n=3; all three being co-177 
carried alongside blaCTX-M-15), as well as blaDHA-1 (n=8; one alongside blaCTX-M-15) and blaSHV-12 178 
(n=6). The narrow spectrum β-lactamases blaOXA-1, blaTEM-1 and inhibitor-resistant variant 179 
blaTEM-33 were found in 53, 82, and one isolate respectively. 180 
AmpC-hyperproducing isolates 181 
All thirteen (5.8%) sequenced isolates, where no CTX-R GOI could be identified, were 182 
presumed to be chromosomal AmpC β-lactamase hyperproducers because they carry 183 
mutations within the ampC promoter/attenuator region previously seen in confirmed AmpC 184 
hyperproducers (Table 3).29, 30 These represented nine different STs, each having one 185 
representative, with the exceptions of the STs 75 and 200 of which there were three 186 
representatives each (Table S2). This indicates a lack of dominant clones in AmpC 187 
hyperproducers identified in this study. If we go on to assume that the 24 isolates negative for 188 
GOIs by PCR are AmpC-hyperproducers, as was found with the thirteen representative 189 
sequenced isolates, then 3.8% of the isolates in this study could be classed as AmpC-190 
hyperproducers. Additionally, one blaCTX-M-15-positive isolate was found to also harbour ampC 191 
promoter changes associated with hyperproduction. 192 
Characterisation of ST131 Isolates  193 
ESBLs and clades 194 
One hundred and one ST131 isolates harboured the following CTX-R mechanisms/alleles; 195 
blaCTX-M-1 (n=1), blaCTX-M-14 (n=4), blaCTX-M-15 (n=61), blaCTX-M-15/blaCMY-60 (n=1), blaCTX-M-27 196 
(n=33). The isolates were broken down into their respective clades (Table 4); ST131-C2 was 197 
dominant (54/101; 53.5%) followed by C1-M27 (M27) (23/101; 22.8%), A (11/101; 10.9%), C1-198 
nM27 (5/101; 5.0%), one clade B, and seven isolates were unclassified. Eighty-eight percent 199 
(89/101) of isolates, and notably all clade C2 isolates, were CIP-R as is a typical characteristic 200 
of this lineage. Two non-ST131 members of the ST131 complex, both of which were blaCTX-M-201 
15-positive ST8313 isolates (a fumC single locus variant (SLV) of ST131), also harboured the 202 
 
 
same chromosomal FQ-R associated mutations in gyrA, parC and parE as are associated with 203 
ST131/C2 – suggesting this ST may be ST131/C2 derived. Previous studies have highlighted 204 
the dominance of ST131 and particularly the clade C2/H30Rx on a worldwide scale.13, 14 Since 205 
its initial description in 2008 in isolates from 3 continents,12, 13 ST131 has been reported across 206 
all inhabited continents.15 The recently described C1 subclade, C1-M27, as characterised by 207 
the presence of a 11,894 bp prophage-like genomic island M27PP1, was initially described in 208 
Japan in 2016 and has been reported in countries in at least three continents: Europe, Asia 209 
and North America, so far.16 The presence of C1-M27 isolates in this study indicates the 210 
expansion of this particular ST131 sublineage into the UK, similarly to that which has been 211 
reported from countries in mainland Europe.31 There was no geographical clustering of C1-212 
M27 positive isolates within our study region. 213 
Virotypes 214 
ST131 has been reported in previous studies to be a highly virulent clone, exhibiting lethality 215 
in mouse sepsis models.18, 32 Virotypes of all 101 ST131 isolates were determined as 216 
previously described.18, 33 Virotype C was most common, represented by 38/101 (37.6%) of 217 
ST131 isolates and predominantly associated with blaCTX-M-27 (28/38 isolates) across clades A 218 
(n=3), C1-M27 (n=22), C1-nM27 (n=4), and one isolate belonged to an unclassified clade. All 219 
blaCTX-M-27-positive isolates belonged to virotype C, with the exception of one isolate for which 220 
a virotype could not be assigned. The association between virotype C and blaCTX-M-27 carriage 221 
is in agreement with a recent study conducted in France.34 Twenty-five isolates belonged to 222 
virotype A, all of which except one harboured blaCTX-M-15. The remaining 38 isolates belonged 223 
to either virotype B (n=1), D (n=1), G (n=8), or were unknown virotypes (n=28). 224 
Genetic context of ESBLs/pAmpC genes 225 
Despite the limitations of short read sequencing, by examining the contigs on which GOIs 226 
were located, we were able to determine the chromosomal or plasmid environments of 227 
ESBLs/pAmpC genes in 85/225 isolates. Forty blaCTX-M genes, of variants blaCTX-M-14 (n=3) and 228 
 
 
blaCTX-M-15 (n=37), were found to be located on the chromosome. These were found in 11 STs 229 
with STs 131 (n=11) and 73 (n=10) being the most represented. Whilst the blaCTX-M genetic 230 
environments were diverse in ST131, in ST73, 9/10 isolates harboured the gene in the same 231 
genomic location, suggesting a high degree of clonality within this ST. Chromosomally 232 
encoded blaCTX-M genes have previously been reported in 12.9% of human isolates in study of 233 
ESBL E. coli performed in Germany, The Netherlands and the UK.35 The remaining GOIs were 234 
found to be located within a relatively diverse range of plasmids and across multiple STs. 235 
Interestingly all six DHA-1-harbouring isolates were found to harbour a similar IncI1 plasmid 236 
which was sequenced to closure during this study, pUB_DHA-1. Read mapping analyses 237 
showed that all six isolates exhibited 95-100% coverage and 98-100% identity against 238 
pUB_DHA-1. 239 
Other important resistance genes found by WGS 240 
Interestingly one ST69 CMY-2-producing isolate was also found to harbour mcr-1. 241 
Susceptibility testing, performed by broth microdilution, revealed that the MIC of colistin 242 
against this isolate is 8 mg/L and so it is colistin resistant. Attempts at transformation of E. coli 243 
DH5 alpha using plasmid DNA extracted from this isolate were successful indicating that mcr-244 
1 is plasmid encoded. Analysis of the genetic environment of mcr-1 found that it is encoded 245 
on an IncI2 plasmid of approximately 62 kb and it lacks the upstream ISApl1 element that was 246 
described in the initial discovery of mcr-1 in China.36 The plasmid itself does not encode any 247 
additional resistance genes and when subjected to NCBI BLAST analysis exhibited ~96% 248 
similarity to mcr-1 encoding plasmids found in both China (pHNGDF93; Genbank Accession 249 
Number MF978388) and Taiwan (p5CRE51-MCR-1; Genbank Accession Number CP021176) 250 
from animal and human origins, respectively. Since initial reports of its discovery in 2015,36 251 
mcr-1 has been reported worldwide in clinical E. coli isolates although remains relatively rare.  252 
Another isolate, a blaCTX-M-14-positive ST38, also encoded the blaOXA-48-like carbapenemase 253 
gene blaOXA-244.37 Transformation attempts using plasmid DNA from this isolate were 254 
unsuccessful and so it was concluded that blaOXA-244 is likely to be chromosomally encoded. 255 
 
 
Disc susceptibility testing showed that this isolate was resistant to ertapenem but susceptible 256 
to both imipenem and meropenem. The presence of the chromosomally-encoded OXA-48-like 257 
carbapenemase blaOXA-244, confirms the observations of a previous study, where OXA-48-like 258 
genes were shown to have become embedded in the ST38 chromosome.38 ST38 is the most 259 
frequent ST associated with OXA-48-like enzymes in the UK.38 260 
Conclusions 261 
Resistance to 3GCs and FQs in E. coli is of increasing concern due to the importance of these 262 
classes of drugs for the treatment of serious infections. Increasing resistance to 3GCs puts 263 
increased pressure and reliance on carbapenems, often referred to as the ‘antibiotics of last 264 
resort’ for serious MDR Gram-negative infections and subsequently the surveillance of these 265 
resistances is essential. As observed in this study and in line with previous reports globally,2 266 
the dissemination of successful clones, and/or ST lineages (clades), is a major cause of CTX-267 
R in urinary isolates from primary care in South West England.  268 
blaCTX-M-positive E. coli have been observed in our study region since initial reports in 2000.39 269 
The prevalence of blaCTX-M genes observed in the CTX-R isolates in this study is reflective of 270 
the observed rates of CTX-M E. coli faecal carriage in healthy adults in the UK, as has been 271 
quantified in previous studies.28, 40 272 
The correlation between CIP-R and CTX-R highlighted here can be largely attributed to the 273 
dominance of successful clones/clades, namely ST131 and ST1193; the majority of both 274 
harbour chromosomal FQ-R mutations. Through WGS of a subset of isolates we have shown 275 
that ST131 clade C2 is dominant and that the recently described ST131 subclade, C1-M27, is 276 
also prevalent despite not previously being described in the UK. 277 
This study is the first analysis of CTX-R E. coli causing CO-UTI performed in a relatively 278 
localised area in South West England and could be useful for informing patient treatment, 279 
alongside resistance information generated in the hospital laboratory, to provide essential data 280 
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  404 
Figure 1. Minimum spanning tree of the MLST profiles of 225 CTX-R E. coli isolates. The shaded areas represent single locus variants (SLVs). 405 
Members of the most prevalent STs (>4 representatives) are labelled and their number of representatives indicated. The diameter of the circle 406 
represents the number of isolates of that particular ST and the coloured segments indicate which CTX-R mechanisms were identified. Thick solid 407 
lines represent SLVs, thin solid lines represent double-locus variants and dashed connecting lines indicate multilocus variants. This figure appears 408 

















Table 1. Beta-lactamase genes detected by multiplex PCRs on 626 CTX-R isolates. 412 


























9 3 1 10 118 44 4 7 1 2 3 8 6 
 413 
Table 2. ESBL/pAmpC variants identified in the 225 isolates subjected to WGS.  414 
Note: 3 isolates harboured both blaCMY-60 and blaCTX-M-15, and one isolate harboured blaDHA-1 415 
and blaCTX-M-15. 416 
 417 
No. of isolates ampC promoter/attenuator mutations Pribnow box 
8 -42C>T, -25G>A, -1C>T, +57C>T TTGACA - 17nt - TATCGT 
2 -28G>A, ins -12 T -13, +22G>T TTGTCA - 17nt - TACAAT 
2 -11C>T, ins -12 T -13, +33G>A, +36G>A TTGTCA - 17nt - TATAAT 
1 -32T>A, +34C>A, +57C>T TTGACA - 16nt - TACAAT 
 418 
Table 3. Mutations found within promoter/attenuator region of the 13 presumed AmpC-419 
hyperproducing isolates subjected to WGS relative to E. coli MG1655 (Genbank Accession 420 




 CTX-R Alleles 










A  11 1 1 4 5  
B  1 1     
C C1-M27 23    23  
C1-nM27 5  3  2  
C2 54   54   
Unclassified  7   4a 3 1a 
Total 101 2 4 62 33 1a 
 425 





















CMY DHA SHV None 
 F 
(n=507) 
334 3 1 2 123 1 6 11 6 20 
 M 
(n=119) 
77 1 2 1 26 0 4 2 2 4 
Total 626 411 4 3 3 149 1 10 13 8 24 
 
 
Table 4.  ST131 clades and CTX-R GOI alleles harboured by 101 isolates subject to WGS. 426 
a One isolate belonging to an ST131 unclassified clade harboured both blaCTX-M-15 and blaCMY-427 
60. 428 
